Table 2 Pathological distribution of primary tumors and suspected metastases in both cohorts

Exploration cohort

Lung (n = 19)

17/1/1 (22^†)

2/0/0 (2^†)

–

Biliary tract (n = 2)

2/0/0 (2^†)

1/1/0 (3^†)

–

Liver (n = 4)

3/1/0 (5^†)

0/1/0 (2^†)

–

Colorectum (n = 17)

17/0/0 (17^†)

8/3/1 (17^†)

–

Stomach (n = 4)

4/0/0 (4^†)

1/0/0 (1^†)

–

Total (n = 46)

50^†

25^†

0^†

Clinical validation cohort

Lung (n = 11)

11/0/0 (11^†)

1/0/1 (4^†)

–

Biliary tract (n = 30)

29/1/0 (31^†)

11/4/0 (19^†)

–

Liver (n = 19)

16/2/1 (23^†)

2/1/0 (4^†)

–

Colorectum (n = 10)

10/0/0 (10^†)

3/3/2/1 (19^†)

1/0/2 (7^†)

Stomach (n = 4)

3/0/1 (6^†)

2/0/0 (2^†)

–

Pancreas (n = 26)

24/2/0 (28^†)

5/0/0 (5^†)

–

Gall bladder (n = 5)

5/0/0 (5^†)

0/1/1 (5^†)

–

Bladder (n = 7)

4/3/0 (10^†)

–

–

Breast (n = 3)

3/0/0 (3^†)

1/0/0 (1^†)

1/0/0 (1^†)

Ovary (n = 4)

3/1/0 (5^†)

–

–

Small intestine (n = 9)

9/0/0 (9^†)

2/0/0 (2^†)

–

Pharynx (n = 3)

3/0/0 (3^†)

0/0/0/0/0/0/1 (7^†)

–

Skin (n = 1)

1/0/0 (1^†)

1/0/0 (1^†)

–

Others (n = 15)*

15/0/0 (15^†)

–

–

Total (n = 147)

160^†

69^†

8^†